Study guide
8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements
ACRP Certified Professional ACRP-CP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: GCP Principles, Roles & Delegation
1.1 The Eleven ICH E6(R3) Principles of GCP & Guideline Structure 1.2 Sponsor & Investigator Responsibilities and Delegation of Authority 1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL) 1.4 CRO Oversight, Vendor Management & Transfer of Regulatory Obligations (TORO)
2 Chapter 2: Essential Records, Source Documentation & Data Confidentiality
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C) 2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness 2.3 Source Documentation, ALCOAC Principles & Medical Record Standards 2.4 Confidentiality, Privacy & Protection of Participant Personal Information
3 Chapter 3: Monitoring, Quality Management & Audits
3.1 Risk-Based Quality Management (RBQM) & Quality Management Systems (QMS) 3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out 3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR) 3.4 Quality Audits, Regulatory Inspections, Non-Compliance & Root Cause Analysis / CAPA
4 Chapter 4: Site Feasibility, Start-Up, Facilities & Laboratory Operations
4.1 Site Feasibility Assessment, Capability Analysis & Investigator Selection 4.2 Contractual Agreements: Clinical Trial Agreements, Budgets, Indemnification & Financial Arrangements 4.3 Site Initiation Preparation, System Access & Regulatory Greenlight 4.4 Protocol Review, Operational Feasibility & Institutional Approvals 4.5 Site Facilities, Equipment Maintenance, Calibration & Trial Supplies 4.6 Biological Samples & Hazardous Goods: Collection, Storage, Disposal & Shipment
5 Chapter 5: Subject Recruitment, Retention & Study Visits
5.1 Subject Recruitment Strategies, Advertising Guidelines & Ethical Constraints 5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence 5.3 Subject Retention, Compliance, Visit Scheduling & Protocol Window Management 5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
6 Chapter 6: Protocol Compliance, Deviations & Site Close-Out
6.1 Protocol Compliance, Waivers vs. Violations & Deviation Management 6.2 Investigational Site Close-Out Activities & Final Reconciliations 6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities
7 Chapter 7: Research Ethics, Vulnerable Populations & Research Integrity
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki 7.2 Ethical Principles: Beneficence, Non-Maleficence, Autonomy, Justice & Equipoise 7.3 Vulnerable Populations (Pediatrics, Pregnant Women, Prisoners, Cognitively Impaired, Economically Disadvantaged) 7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
8 Chapter 8: Informed Consent & Institutional Review Boards (IRB/IEC)
8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements 8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements 8.3 IRB/IEC Composition, Functions, Review Types (Full, Expedited, Exempt) & Continuing Review
9 Chapter 9: Safety Reporting & Adverse Event Management (ICH E2A)
9.1 Adverse Events (AE) vs. Adverse Drug Reactions (ADR) & Serious Adverse Events (SAE) Definitions 9.2 Causality Assessment, Expectedness, Reference Safety Information (RSI) & SUSARs 9.3 Expedited Reporting Timelines (7-day fatal/life-threatening, 15-day other serious) & Periodic Safety Updates (DSUR)
10 Chapter 10: Investigational Product (IP) Management & Accountability
10.1 Investigational Product Lifecycle, Labeling, Packaging & Blinding Procedures 10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody 10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures 10.4 Emergency Unblinding (Code Breaking) Protocols & Subject Safety Procedures
11 Chapter 11: Regulatory Frameworks, Submissions & Product Reference Information
11.1 Stakeholders, Regulatory Institutions & Global Frameworks in Clinical Research 11.2 Protocol Submission, Approval & Amendment Processes 11.3 Investigator's Brochure, Instructions for Use & Reference Product Information 11.4 Regulatory Reporting Requirements Before and After Marketing Authorisation
12 Chapter 12: Clinical Data Management, EDC & Electronic Records
12.1 Electronic Data Capture (EDC), eCRF Design & Clinical Data Management Systems (CDMS) 12.2 Computerised Systems, Data Governance & Audit Trails (ICH E6(R3) Annex 1 §4) 12.3 Data Validation, Edit Checks, Discrepancy / Query Management & Resolution 12.4 Medical Coding (MedDRA, WHO Drug), SAE Reconciliation, Data Transfer & Database Lock
13 Chapter 13: Trial Design, Biostatistics, Data Monitoring & Transparency
13.1 Phases of Clinical Research (Phase 0, I, II, III, IV) & Translational Medicine 13.2 Study Designs: Parallel, Crossover, Factorial, Adaptive & Non-Inferiority / Equivalence 13.3 Randomization Schemes, Stratification, Blinding Methods & Minimizing Bias 13.4 Endpoints (Primary, Secondary, Surrogate, Composite), Sample Size & Biostatistical Concepts (p-values, CI, ITT vs PP) 13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones 13.6 Trial Registration, Results Transparency & Communicating Results to Participants
8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements
Key Takeaways Explain This Topic AI
A legally acceptable representative (LAR) is defined in the ICH E6(R3) glossary as an individual or juridical or other body authorised under applicable law to consent on behalf of a prospective participant; US rules (21 CFR 50.3(l)) call this a legally authorized representative.
Pediatric participants cannot give legal consent; they provide Assent (affirmative agreement), which must be paired with Parental Permission governed by 45 CFR 46 Subpart D and 21 CFR 50 Subpart D.
Research involving greater than minimal risk with no direct benefit but likely to yield generalizable knowledge (Category 3 / 21 CFR 50.53) requires permission from BOTH parents unless one is deceased, unknown, incompetent, or not reasonably available.
Emancipated minors and mature minors under state law possess legal authority to consent for themselves without parental permission.
When a pediatric subject reaches the legal age of majority (typically 18 years) while enrolled in a study, parental permission expires and the subject must be re-consented as an adult using an IRB-approved adult ICF to continue.
Last updated: October 2026
Assent in Minors & Legally Acceptable Representative (LAR) Requirements
Exam scope note: This section cites national regulations (for example US Code of Federal Regulations provisions) because they shape day-to-day practice. ACRP states the ACRP-CP exam is referenced only to ICH Guidelines and that no country-specific framework is tested. Treat those citations as professional context; the provision examined here is ICH E6(R3) Principle 2.1 and Annex 1 section 2.8 , together with ICH E11(R1) , which E6(R3) cites directly on assent from minors.
Quick Reference: When a prospective clinical trial subject lacks the legal or cognitive capacity to provide autonomous informed consent—such as a minor child or an incapacitated adult—special regulatory protections are activated. For adults lacking decision-making capacity, consent must be obtained from a legally acceptable representative (LAR) authorized under applicable law (ICH E6(R3) glossary; the US term in 21 CFR 50.3(l) is legally authorized representative, determined by state/local law). For pediatric subjects, research is governed by Subpart D regulations (21 CFR 50 Subpart D / 45 CFR 46 Subpart D), requiring Parental Permission (from one or both parents depending on risk-benefit category) paired with child Assent .
On the ACRP-CP (ACRP Certified Professional) exam, questions concerning LAR authority and pediatric research frequently test your mastery of surrogate hierarchies, parental permission thresholds, minor assent documentation, and the critical transition when a child turns 18 during active trial participation.
- 1. Legally Acceptable Representatives (LAR): Definition & Authority
- Regulatory Definition (ICH E6(R3) Glossary)
"An individual or juridical or other body authorised under applicable law to consent, on behalf of a prospective participant, to the participant's participation in the clinical trial."
US rules (21 CFR 50.3(l)) define the same role as a legally authorized representative : "an individual or judicial or other body authorized under applicable law to consent on behalf of a prospective subject to the subject's participation in the procedure(s) involved in the research." ┌───────────────────────────────────────────────────────────────────────────┐
- │ WHEN CAN AN LAR BE UTILIZED? │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 1. Cognitively impaired adults (e.g., advanced Alzheimer's disease) │
- │ 2. Acutely incapacitated trauma / intensive care patients (ICU / coma) │
- │ 3. Individuals with court-appointed legal guardians for medical decisions │
- │ CRITICAL RULE: An LAR can NEVER be used to override a competent adult's │
- │ explicit refusal to participate in a clinical trial! │
- └───────────────────────────────────────────────────────────────────────────┘
- State Law Primacy & Surrogate Hierarchy
Federal regulations do not define who qualifies as an LAR; instead, they explicitly defer to applicable state and local law . Clinical research sites must follow their specific state's statutory hierarchy of surrogate decision-makers. A standard statutory hierarchy typically operates as follows: 1. Court-Appointed Legal Guardian (with specific healthcare decision authority)
- └── 2. Designated Healthcare Proxy / Durable Power of Attorney for Healthcare (DPOA)
- └── 3. Legal Spouse
- └── 4. Adult Children (majority agreement among available adult children)
- └── 5. Parents
- └── 6. Adult Siblings
- └── 7. Nearest Living Adult Relative
Exam Key Point: A general "Power of Attorney (POA) for Finances" does not grant authority to consent to clinical research. Only a Durable Power of Attorney for Healthcare (DPOA) , a designated healthcare proxy, or a court-appointed guardianship specifically including medical decision-making empowers an individual to act as an LAR for clinical trials.
2. Pediatric Research Protections: Subpart D Categories
Children are classified as a vulnerable population because they lack legal capacity to consent and may be vulnerable to coercion. Federal regulations ( 21 CFR 50 Subpart D for FDA-regulated products and 45 CFR 46 Subpart D for HHS-funded research) divide pediatric research into four distinct risk-benefit categories :
Subpart D Category Risk / Benefit Determination Regulatory Citation Parental Permission Required Assent Required?
Category 1 Not greater than minimal risk 21 CFR 50.51; 45 CFR 46.404 One Parent permission is sufficient Yes , if capable of assent
Category 2 Greater than minimal risk, but presents prospect of direct benefit to individual subject 21 CFR 50.52; 45 CFR 46.405 One Parent permission is sufficient Yes , if capable of assent
Category 3 Greater than minimal risk, NO prospect of direct benefit , but likely to yield generalizable knowledge about subject's disorder/condition 21 CFR 50.53; 45 CFR 46.406 BOTH Parents must give permission (unless exception applies) Yes , if capable of assent
Category 4 Not otherwise approvable , but presents opportunity to understand, prevent, or alleviate a serious problem 21 CFR 50.54; 45 CFR 46.407 BOTH Parents must give permission + requires HHS/FDA Secretarial Panel Approval Yes , if capable of assent
Exceptions to the Two-Parent Permission Rule (Category 3 & 4):
Under 21 CFR 50.55(e)(2) , permission from both parents is required under Categories 3 and 4 UNLESS :
- One parent is deceased;
- One parent is unknown;
- One parent is incompetent;
One parent is not reasonably available (e.g., deployed overseas in military service without communication access); OR
Only one parent has legal custody of the child (e.g., sole legal custody granted by a court decree).
Exam Watchout: Divorced parents who share joint legal custody must both sign the parental permission form for Category 3 research. If one parent with joint custody refuses, the child cannot be enrolled, regardless of how enthusiastically the other parent agrees.
- 3. The Pediatric Assent Process & Age Thresholds
- Defining Assent
Assent is defined as a child's affirmative agreement to participate in research. Mere failure to object or passive silence cannot be construed as assent. ┌───────────────────────────────────────────────────────────────────────────┐
- │ AGE-APPROPRIATE ASSENT TIERS │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ AGE < 7 YEARS: │
- │ • Assent typically not required; child evaluated for developmental state │
- │ • Parental permission alone governs enrollment │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ AGE 7 – 11 YEARS (Simple / Visual Assent): │
- │ • Simplified 1-page form with plain language, illustrations, or comics │
- │ • Explains what will happen, what hurts (blood draws), and voluntariness │
- │ • Verbal or written assent documented per IRB policy │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ AGE 12 – 17 YEARS (Adolescent Assent): │
- │ • More comprehensive written document describing trial rationale, │
- │ randomization, side effects, study visit schedule, and right to stop │
- │ • Signed and dated written assent by the adolescent │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ AGE 18+ YEARS (Legal Adulthood): │
- │ • Full adult Informed Consent Form signed by the participant │
- └───────────────────────────────────────────────────────────────────────────┘
When Can the IRB Waive Pediatric Assent?
Under 21 CFR 50.55(c) , the IRB may waive the assent requirement if:
The capability of some or all of the children is so limited that they cannot reasonably be consulted (e.g., severe developmental delay, acute coma);
The intervention or procedure involved in the research holds out a prospect of direct benefit that is important to the health or well-being of the child and is available only in the context of the research (e.g., life-saving pediatric oncology protocol with no commercial alternative); OR
The research meets standard minimal-risk waiver criteria under 45 CFR 46.116.
Pediatric Dissent vs. Parental Permission
If a clinical trial involves no prospect of direct benefit (e.g., Category 1 or Category 3 pharmacokinetic studies) and an assenting-age child dissents (refuses to participate or says "no") , the child's dissent must be respected . Parents cannot force a child to participate in non-beneficial research.
4. Emancipated Minors vs. Mature Minors
Not all individuals under 18 years of age require parental permission. State law establishes critical legal exemptions: ┌───────────────────────────────────────────────────────────────────────────┐
- │ SPECIAL MINOR LEGAL STATUSES │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 1. EMANCIPATED MINORS: │
- │ • Recognized by court declaration, legal marriage, active military │
- │ enlistment, or complete financial self-sufficiency (per state law). │
- │ • Possess FULL legal authority of an adult; consent for themselves. │
- │ • NO parental permission is required or permitted. │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 2. MATURE MINOR DOCTRINE / STATUTORY CONSENT: │
- │ • Specific state laws allowing minors to consent independently for │
- │ certain medical treatments: STI testing/treatment, contraception, │
- │ substance abuse treatment, and outpatient mental health. │
- │ • In research studying these specific conditions, IRBs may waive │
- │ parental permission if obtaining parental permission would breach │
- │ minor confidentiality and pose harm (45 CFR 46.408(c)). │
- └───────────────────────────────────────────────────────────────────────────┘
- Wards of the State (21 CFR 50.56 / 45 CFR 46.409)
Children who are wards of the state or any other agency, institution, or entity can be included in research approved under Category 3 ( 21 CFR 50.53 ) or Category 4 ( 21 CFR 50.54 ) ONLY IF such research is:
Related to their status as wards; OR
Conducted in schools, camps, hospitals, institutions, or similar settings in which the majority of children involved as subjects are not wards.
Independent Advocate Mandate: The IRB must require the appointment of an independent Advocate for each child who is a ward, who acts in addition to any other individual acting on behalf of the child as guardian or in loco parentis.
5. Transition of Minors Who Reach the Legal Age of Majority (Turning 18)
One of the most frequently missed operational requirements in longitudinal pediatric trials occurs when a child reaches the legal age of majority (18 years old) while actively participating in a clinical trial. ┌───────────────────────────────────────────────────────────────────────────┐
- │ PEDIATRIC TRANSITION AT 18TH BIRTHDAY │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ • Legal Reality: At age 18, parental permission AUTOMATICALLY EXPIRES. │
- │ • Operational Mandate: The subject is now a legal adult. │
- │ • Required Action: The site must RE-CONSENT the participant using the │
- │ IRB-approved adult Informed Consent Form at the very next contact. │
- │ • If Not Re-Consented: No further study interventions, blood draws, or │
- │ active data collection can occur until adult consent is executed. │
- └───────────────────────────────────────────────────────────────────────────┘
OHRP & FDA Regulatory Consensus on Aging-Up:
Informed consent is an ongoing process. Parental permission is legally valid only while the individual is a minor under state law.
As soon as the subject turns 18, the investigator must seek and obtain autonomous informed consent from the now-adult participant using the standard adult ICF.
If the subject chooses not to sign the adult ICF, they have exercised their autonomous right to withdraw, and no further study-related procedures or interventions may be performed on that individual.
6. Realistic Clinical Scenario & ACRP-CP Critical Analysis
Scenario: A 15-year-old high school student with moderate persistent asthma is evaluated for enrollment in a Phase III trial evaluating an investigational biologic. The protocol is classified by the IRB under 21 CFR 50.53 / 45 CFR 46.406 (Category 3: Greater than minimal risk with no direct benefit, but offering generalizable knowledge) because it involves invasive bronchoscopy biopsies without therapeutic intent.
The student's mother attends the screening visit, provides written parental permission, and expresses great enthusiasm. The student signs the adolescent assent form. The parents are divorced with joint legal custody. The father lives two hours away and, when reached by phone, states: "I do not want my child undergoing invasive lung biopsies for research. I refuse to sign."
ACRP-CP Critical Evaluation & Decision Path:
Regulatory Mandate (Subpart D Category 3): Under 21 CFR 50.53 and 50.55(e)(2), Category 3 research strictly mandates permission from BOTH parents unless one is deceased, unknown, incompetent, or not reasonably available, or one parent has sole legal custody.
Legal Custody Status: Because the parents share joint legal custody, the father possesses legal standing.
Father Availability: Living two hours away and communicating by phone confirms the father is "reasonably available" and competent.
Compliance Outcome: Because the father refuses to give permission, the requirement for two-parent permission cannot be met. The site cannot enroll the child , and proceeding with enrollment based on the mother's signature alone is a major regulatory violation.